Specifically targeting ERK1 or ERK2 kills Melanoma cells

BACKGROUND: Overcoming the notorious apoptotic resistance of melanoma cells remains a therapeutic challenge given dismal survival of patients with metastatic melanoma. However, recent clinical trials using a BRAF inhibitor revealed encouraging results for patients with advanced BRAF mutant bearing m...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Jianzhong, Xin, Hong, Nickoloff, Brian J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305427/
https://www.ncbi.nlm.nih.gov/pubmed/22277029
http://dx.doi.org/10.1186/1479-5876-10-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3305427/
https://www.ncbi.nlm.nih.gov/pubmed/22277029
http://dx.doi.org/10.1186/1479-5876-10-15

Ejemplares similares